Eisai to pull obesity drug after post-marketing study reveals increased cancer risk
The voluntary withdrawal was in response to an FDA request. Eisai said its interpretation of the data differed from the agency's, but the drug's original developer had called off pursuit of European approval when regulators there pointed to potential tumor risk from long-term use.